Facebook Icon Print Created with Sketch. Twitter Icon Created with Sketch. Created with Sketch. LinkedIn Icon Green Check Icon Created with Sketch. YouTube Icon Right Arrow Icon Mobile Menu Icon Chevron Right Icon Phone Icon Health Study Area: AutoImmune Disease Health Study Area: Blood Cancer Health Study Area: Cardiovascular Disease Health Study Area: Fibrosis Health Study Area: Gastrointestinal Cancer Health Study Area: Genitourinary Health Study Area: Head and Neck Cancer Health Study Area: Lung Cancer Health Study Area: Melanoma Health Study Area: Women's Cancer For Caregivers For Clinicians Communities FAQs For Parents For Patients Chevron Icon Bookmark Icon Map Icon Share Icon Direction Arrow Icon Direction Arrow Icon Page Icon Location Icon Search Icon External Link Icon Help Icon Error Icon Glossary Email Icon Gender Both Gender Male Gender Female Created with Sketch. Created with Sketch.

Please Log In/Join Now first, and then use this function!


Assessment of Gut Absorption of Experimental Medication BMS-986165 in Healthy Males - IM011-019

Updated: 12 March, 2019   |   ClinicalTrials.gov

Print Friendly Summary

Print this page and the trial guide to help you talk with your doctor.
Use the Study Participant's Guide to navigate the process of participating in a clinical trial. Understand key factors to consider before deciding and get questions to ask your healthcare team.

Trial Details

  • Phase 1


  • Gender(s)

  • 18-45

    Age Range

  • 1


  • Recruiting

Treatment Options

Study Arms
Experimental: Formulation A
Drug: BMS-986165
Experimental: Formulation B
Drug: BMS-986165
Experimental: Formulation C
Drug: BMS-986165
Experimental: Formulation D
Drug: BMS-986165
Experimental: Formulation E
Drug: BMS-986165
Experimental: Formulation F
Drug: BMS-986165
Experimental: Formulation G
Drug: BMS-986165
Experimental: Formulation H
Drug: BMS-986165

Key Eligibility Criteria

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: - Body mass index of 18.0 to 32.0 kg/m2, inclusive, and weight ≥ 50 kg, at screening - Estimated glomerular filtration rate (eGFR) > 80 mL/min/1.732 calculated with the Chronic Kidney Disease Epidemiology Collaboration formula Exclusion Criteria: - Any significant acute or chronic medical illness - Current or recent (within 3 months of study drug administration) disease of the gut that, in the opinion of the Investigator or Medical Monitor, could impact upon the absorption of study drug - Acute diarrhea, or constipation within 3 weeks prior to randomization - Any major surgery within 4 weeks of randomization Other protocol defined inclusion/exclusion criteria could apply

Have questions? Email Us

Have questions?
Email Us